Back to today’s briefing

Story perspectives

Imagion Stock Soars 35% on FDA Breast Cancer Breakthrough

7/15/2025

50 4

Summary

Story summary

Imagion Biosystems' stock skyrocketed by 35% following encouraging FDA feedback on its phase II trial for breast cancer diagnostics using innovative Magsense technology. This trial focuses on detecting Her-2 positive breast cancer through advanced nanoparticles. In a related success, Biome Australia celebrated a remarkable 69% surge in international revenue, setting its sights on achieving $75 million in annual revenue by 2027.

1 of 1

Story summary

Imagion Biosystems' stock skyrocketed by 35% following encouraging FDA feedback on its phase II trial for breast cancer diagnostics using innovative Magsense technology. This trial focuses on detecting Her-2 positive breast cancer through advanced nanoparticles. In a related success, Biome Australia celebrated a remarkable 69% surge in international revenue, setting its sights on achieving $75 million in annual revenue by 2027.